2025 | Heart Failure | Preserved Ejection Fraction | Treatment Algorithms: Claims Data Analysis | US | 2025
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology has improved, pharmacological treatments with proven outcomes and benefits have been elusive. Drug treatment focuses primarily on managing the comorbidities, and first-line treatment typically consists of RAAS inhibitors, beta blockers, and diuretics. The addition of a second-line treatment may be required to better manage the disease. The standard of care for HFpEF is changing with the availability of the Entresto (sacubitril / valsartan) and SGLT-2 inhibitors for this population. This report provides important insight into how these agents are used in the management of HFpEF and how practices are evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFpEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFpEF patients?
- How have SGLT-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of HFpEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HFpEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
Markets covered: United States
Key companies: Pfizer, Merck & Co., Novartis, GSK, AstraZeneca, Johnson & Johnson Innovative Medicine, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, MRAs, diuretics, CCBs, nitrates, Entresto (sacubitril / valsartan), SGLT-2 inhibitors
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
